16+
Major trials tracked
Immunology & inflammation · Live ClinicalTrials.gov data
Risankizumab (Skyrizi) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 risankizumab trials on ClinicalTrials.gov by enrolment, 4 of them actively recruiting. The next phase 3 primary completion among them is expected Jan 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
11
Phase 3 trials
4
Actively recruiting
Jan 2027
Next phase 3 primary completion
10,781
Participants across trials
AbbVie
Lead sponsor by trial count
risankizumab (16)9 active2016–2031
risankizumab
'16
'18
'20
'22
'24
'26
'28
'30
risankizumab
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3
LIMMITLESSP3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic TreatmentP3
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisP2
COMMANDP3
KEEPsAKE2P3
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabP3
SOPRANO-CDP4
PATHFINDERP4
AFFIRMP3
IMMpactfulP4
Target CDP2
IZAR-2P3
REVAMPP3
Risankizumab for Fibrostenotic Crohn's Disease TreatmentP3
Upcoming readouts
8 ahead · risankizumab
Select a trial to load its full ClinicalTrials.gov record.
Key risankizumab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05928039 | PATHFINDER — PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominan… | Phase 4 | Recruiting | Jul 2027 |
| NCT05169593 | SOPRANO-CD — Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy | Phase 4 | Recruiting | Oct 2027 |
| NCT06333860 | IMMpactful — A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants… | Phase 4 | Completed | Mar 2026 |
| NCT06641089 | IZAR-2 — Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | Recruiting | Jan 2027 |
| NCT03671148 | KEEPsAKE2 — A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who … | Phase 3 | Active, not recruiting | Jun 2020 |
| NCT06063967 | AFFIRM — A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatme… | Phase 3 | Active, not recruiting | Mar 2027 |
| NCT06880744 | REVAMP — A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Coli… | Phase 3 | Active, not recruiting | Aug 2027 |
| NCT07177118 | Risankizumab for Fibrostenotic Crohn's Disease Treatment | Phase 3 | Not yet recruiting | Jun 2028 |
| NCT03398135 | COMMAND — A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | Phase 3 | Active, not recruiting | Sept 2028 |
| NCT02684357 | BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque … | Phase 3 | Completed | Dec 2016 |
| NCT02694523 | BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Seve… | Phase 3 | Completed | Aug 2017 |
| NCT03104413 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active C… | Phase 3 | Completed | Nov 2020 |
Related drug pipelines
FAQ
- How many clinical trials are running for risankizumab?
- ClinicalTrials.gov lists more than 16 phase 2–4 risankizumab trials. This page tracks the 16 largest by enrolment: 2 phase 2, 11 phase 3, and 3 phase 4 among them, with 4 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare risankizumab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.